This study is a national secondary data analysis to determine the prevalence of diagnosed and undiagnosed CKD in German primary care offices in a patient population at high risk for the development and progression of CKD. Furthermore, it addresses the question of how CKD screening, monitoring and treatment of these patients is conducted within the German primary care setting.
The study does not attempt to test any specific a priori hypothesis; it is descriptive only. Data on general patient characteristics, health insurance details, participation in disease management programs and/or family doctor-centred care, diagnoses, prescriptions, surgeries, and procedures, used billable services and laboratory test results are documented during daily routine by the physician. The data used in this setting are part of routine visits, dating back a maximum of 24 months from the date of first data transfer within the study period.
Study Type
OBSERVATIONAL
Enrollment
800,211
Research Site
Koblenz, Germany
Percentage of patients with diagnosed CKD
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with undiagnosed CKD
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with undiagnosed or diagnosed CKD
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients that fulfil CKD definition according to KDIGO (Kidney Disease: Improving Global Outcomes)
To assess the prevalence of diagnosed and undiagnosed CKD among all eligible patients at high risk for the development and progression of CKD
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Average number of serum creatinine measurements per patient per year (52 weeks) in the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Average number of UACR measurements per patient per year (52 weeks) during the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with no, one, or at least two serum creatinine measurements among all eligible patients during the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with no, one, or at least two UACR measurements among all eligible patients during the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients who did not have serum creatinine and UACR determined at least once
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients in whom both serum creatinine and UACR were determined at least once
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients in whom both serum creatinine and UACR were determined at least twice
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with at least two serum creatinine measurements with an interval of at least three months among all eligible patients in the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with at least two UACR measurements with an interval of at least three months among all eligible patients in the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with at least two UACR and serum creatinine measurements with an interval of at least three months among all eligible patients in the study period
To evaluate the use of CKD-related laboratory diagnostics in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Age at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Sex at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
BMI at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Concurrent medication at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Comorbidities at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
eGFR values at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
UACR values at index date
To describe baseline characteristics among patients with diagnosed and undiagnosed CKD at index date
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients among diagnosed or undiagnosed CKD patients that are treated with either/or renin-angiotensin-system-inhibitors (ACEi, ARB), SGLT2i, statin or selective mineralocorticoid receptor antagonist at index date
To evaluate the use of medication to treat CKD among patients with diagnosed and undiagnosed CKD
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients among diagnosed or undiagnosed CKD patients that are newly initiated with either/or renin-angiotensin-system-inhibitors (ACEi, ARB), SGLT2i, statin, selective mineralocorticoid receptor antagonist within 6 months after index date
To evaluate the use of medication to treat CKD among patients with diagnosed and undiagnosed CKD
Time frame: Dating back a maximum of 24 months from the date of first data transfer
Percentage of patients with impaired kidney function
To assess the prevalence of impaired kidney function in all eligible patients
Time frame: Dating back a maximum of 24 months from the date of first data transfer